ASCO 2020 virtual education, progression following immunotherapy, single-agent VEGF-TKI agents, TIVO-3 trial of tivozanib versus sorafenib, immunotherapeutic approaches, HCRN GU16-260 trial, phase II trial of lenvatinib and pembrolizumab, phase III CONTACT-03 trial, MK-6482 a selective small molecular inhibitor of HIF-2alpha
Daniel Spratt explains advances in radiation oncology for prostate cancer, explaining how techniques have evolved from whole pelvis radiation with high toxicity to conformal therapies…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC The Current Treatment Landscape in Metastatic Prostate Cancer – Andrew Armstrong…
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease.…
Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard’s work focuses on two main areas: analyzing tumor samples…
At the 2024 UCSF-UCLA PSMA Conference, Michael Morris reviews the VISION and TheraP trials, underscoring their significance in advancing PSMA PET imaging and radioligand therapy…
Non Muscle Invasive Bladder Cancer (NMIBC), Sequential Gemcitabine and Docetaxel, Bacillus Calmette-Guérin (BCG), Gem/Doce. global BCG supply shortage, radical cystectomy, efficacy of sequential Gem/Doce treatment…
Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent,…
Sam Chang engages with Josh Meeks to discuss nadofaragene firadenovec’s role in treating BCG-unresponsive bladder cancer. They consider the significance of clinical trials and FDA…
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal…
